Stability and solidification of thymol-loaded self-microemulsifying drug delivery system
| Authors | |
|---|---|
| Year of publication | 2024 |
| Type | Appeared in Conference without Proceedings |
| MU Faculty or unit | |
| Citation | |
| Description | Self-emulsifying drug delivery systems (SEDDS) have gained recognition as a crucial approach to enhancing the bioavailability of poorly water-soluble drugs. Thymol boasts a plethora of biological effects, such as anti-inflammatory, antioxidant, immunomodulatory, and analgesic properties. Thymol is a GRAS candidate for preventing and treating inflammatory bowel diseases. Given their limited bioavailability, thymol presents a promising candidate for inclusion in self-emulsifying systems. Nevertheless, liquid SEDDS pose challenges, including the potential irritation caused by a high surfactant content on the gastrointestinal mucosa, reduced formulation stability, and complexities in handling. Solid SEDDS, conversely, are solidified self-emulsifying formulations achieved by converting liquid SEDDS into self-emulsifying powders or particles. Neusilin® US2 was chosen as the solid carrier for thymol SMEDDS formulation. The optimized T-SMEDDS formulations underwent long-term stability tests, and six months stability was demonstrated. The optimal ratio of T-SMEDDS formulation with the solid carrier Neusilin® US2 was 2:1. In vitro dissolution characteristics was determined using biorelevant media FaSSIF. The release of more than 85% of thymol from the T-SMEEDS formulation within 15 minutes indicates a reasonable presumption for enhanced thymol bioavailability in the biosystem. |
| Related projects: |